Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Antiepileptic Drugs: Potassium Channel Activators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Cholesterol: Significance and Regulation
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Brian A Bergmark1, Nicholas A Marston1, Thomas A Prohaska1
1From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston (B.A.B., N.A.M., A.Z., F.A.M., S.A.M., E.L.G., S.Z., R.P.G., M.S.S.); Ionis Pharmaceuticals, Carlsbad (T.A.P., V.J.A., E.K.-P., S.T.), and the Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla (S.T.) - both in California; and the Department of Medicine, Université de Montréal and Ecogene-21 Clinical Research Centre, Quebec, QC, Canada (D.G.).
在患有高甘油三血症的患者中,Olezarsen有效降低了甘油三和阿波利波蛋白C-III水平. 这项研究表明,显著降低甘油三,没有重大安全问题,解决未满足的临床需求.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: